UCB (UCBJF) Expected to Announce Earnings on Thursday

UCB (OTCMKTS:UCBJF) is expected to announce its resultson Thursday, July 30th. Analysts expect the company to announce earnings of $5.81 per share and revenue of $4.6379 billion for the quarter.

UCB Price Performance

Shares of UCBJF opened at $277.44 on Thursday. UCB has a 1-year low of $200.21 and a 1-year high of $345.39. The company’s fifty day simple moving average is $292.55 and its 200 day simple moving average is $300.77. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19.

Wall Street Analysts Forecast Growth

Separately, Piper Sandler reissued a “neutral” rating on shares of UCB in a research report on Wednesday. Six analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.